(PRGO) Perrigo - Overview
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic | Exchange NYSE (USA) | Currency USD | Market Cap: 1.328m | Total Return -62.8% in 12m
Stock: Health, Wellness, Nutrition, Oral Care, Skin Care
| Risk 5d forecast | |
|---|---|
| Volatility | 36.4% |
| Relative Tail Risk | -12.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -2.13 |
| Alpha | -74.86 |
| Character TTM | |
|---|---|
| Beta | 0.582 |
| Beta Downside | 0.358 |
| Drawdowns 3y | |
|---|---|
| Max DD | 73.55% |
| CAGR/Max DD | -0.43 |
EPS (Earnings per Share)
Revenue
Description: PRGO Perrigo March 04, 2026
Perrigo Company PLC (PRGO) is a consumer self-care company. It provides over-the-counter (OTC) health and wellness products across the United States, Europe, and other international markets. The company operates through two primary segments: Consumer Self-Care Americas and Consumer Self-Care International. The OTC market is characterized by direct-to-consumer sales without a prescription, often through pharmacies and retail chains.
Perrigos product portfolio is diverse, encompassing upper respiratory treatments, nutritional products (including infant formula), digestive health aids, pain relievers, sleep aids, and oral care items. It also offers healthy lifestyle products, skincare solutions, womens health products, vitamins, minerals, and supplements. The companys business model includes both branded products and contract manufacturing services, supplying goods to major retail drug, supermarket, and mass merchandise chains, as well as e-commerce platforms and wholesalers. This diversified product offering helps mitigate risks associated with reliance on a single product category.
Key brands include Compeed, Mederma, Nasonex, and Opill. The company was founded in 1887 and is headquartered in Dublin, Ireland. Further research on platforms like ValueRay can provide deeper insights into PRGOs financial performance and market position.
Headlines to watch out for
- Infant formula sales impact revenue and market share
- OTC product demand sensitive to consumer health trends
- Regulatory approvals crucial for new product launches
- International sales growth drives overall company performance
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -1.43b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.84 > 1.0 |
| NWC/Revenue: 41.96% < 20% (prev 32.87%; Δ 9.08% < -1%) |
| CFO/TA 0.03 > 3% & CFO 238.5m > Net Income -1.43b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (138.5m) vs 12m ago 0.65% < -2% |
| Gross Margin: 35.14% > 18% (prev 0.35%; Δ 3.48k% > 0.5%) |
| Asset Turnover: 46.78% > 50% (prev 45.33%; Δ 1.45% > 0%) |
| Interest Coverage Ratio: -6.99 > 6 (EBITDA TTM -828.0m / Interest Expense TTM 162.5m) |
Altman Z'' -0.32
| A: 0.21 (Total Current Assets 2.80b - Total Current Liabilities 1.01b) / Total Assets 8.54b |
| B: -0.43 (Retained Earnings -3.68b / Total Assets 8.54b) |
| C: -0.12 (EBIT TTM -1.14b / Avg Total Assets 9.09b) |
| D: 0.53 (Book Value of Equity 2.94b / Total Liabilities 5.60b) |
| Altman-Z'' Score: -0.32 = B |
Beneish M -3.34
| DSRI: 0.98 (Receivables 612.8m/642.3m, Revenue 4.25b/4.37b) |
| GMI: 1.00 (GM 35.14% / 35.27%) |
| AQI: 0.87 (AQ_t 0.55 / AQ_t-1 0.63) |
| SGI: 0.97 (Revenue 4.25b / 4.37b) |
| TATA: -0.19 (NI -1.43b - CFO 238.5m) / TA 8.54b) |
| Beneish M-Score: -3.34 (Cap -4..+1) = AA |
What is the price of PRGO shares?
Over the past week, the price has changed by -6.41%, over one month by -32.54%, over three months by -28.32% and over the past year by -62.84%.
Is PRGO a buy, sell or hold?
- StrongBuy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PRGO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17 | 76.3% |
| Analysts Target Price | 17 | 76.3% |
PRGO Fundamental Data Overview March 21, 2026
P/S = 0.3123
P/B = 0.4525
P/EG = 1.1418
Revenue TTM = 4.25b USD
EBIT TTM = -1.14b USD
EBITDA TTM = -828.0m USD
Long Term Debt = 3.60b USD (from longTermDebt, last quarter)
Short Term Debt = 62.3m USD (from shortTermDebt, last quarter)
Debt = 3.97b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.44b USD (from netDebt column, last quarter)
Enterprise Value = 4.77b USD (1.33b + Debt 3.97b - CCE 531.6m)
Interest Coverage Ratio = -6.99 (Ebit TTM -1.14b / Interest Expense TTM 162.5m)
EV/FCF = 32.84x (Enterprise Value 4.77b / FCF TTM 145.1m)
FCF Yield = 3.04% (FCF TTM 145.1m / Enterprise Value 4.77b)
FCF Margin = 3.41% (FCF TTM 145.1m / Revenue TTM 4.25b)
Net Margin = -33.51% (Net Income TTM -1.43b / Revenue TTM 4.25b)
Gross Margin = 35.14% ((Revenue TTM 4.25b - Cost of Revenue TTM 2.76b) / Revenue TTM)
Gross Margin QoQ = 32.64% (prev 36.14%)
Tobins Q-Ratio = 0.56 (Enterprise Value 4.77b / Total Assets 8.54b)
Interest Expense / Debt = 0.75% (Interest Expense 29.9m / Debt 3.97b)
Taxrate = 21.0% (US default 21%)
NOPAT = -896.9m (EBIT -1.14b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.76 (Total Current Assets 2.80b / Total Current Liabilities 1.01b)
Debt / Equity = 1.35 (Debt 3.97b / totalStockholderEquity, last quarter 2.94b)
Debt / EBITDA = -4.15 (negative EBITDA) (Net Debt 3.44b / EBITDA -828.0m)
Debt / FCF = 23.69 (Net Debt 3.44b / FCF TTM 145.1m)
Total Stockholder Equity = 4.05b (last 4 quarters mean from totalStockholderEquity)
RoA = -15.68% (Net Income -1.43b / Total Assets 8.54b)
RoE = -35.16% (Net Income TTM -1.43b / Total Stockholder Equity 4.05b)
RoCE = -14.82% (EBIT -1.14b / Capital Employed (Equity 4.05b + L.T.Debt 3.60b))
RoIC = -11.65% (negative operating profit) (NOPAT -896.9m / Invested Capital 7.70b)
WACC = 2.46% (E(1.33b)/V(5.30b) * Re(8.03%) + D(3.97b)/V(5.30b) * Rd(0.75%) * (1-Tc(0.21)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.10%
[DCF] Terminal Value 86.40% ; FCFF base≈184.9m ; Y1≈186.0m ; Y5≈199.7m
[DCF] Fair Price = 18.10 (EV 5.93b - Net Debt 3.44b = Equity 2.49b / Shares 137.6m; r=6.0% [WACC]; 5y FCF grow 0.12% → 3.0% )
EPS Correlation: 35.38 | EPS CAGR: 25.35% | SUE: -0.20 | # QB: 0
Revenue Correlation: -45.64 | Revenue CAGR: 0.86% | SUE: 0.67 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.39 | Chg7d=-0.165 | Chg30d=-0.165 | Revisions Net=-1 | Analysts=3
EPS current Year (2026-12-31): EPS=2.24 | Chg7d=-0.402 | Chg30d=-0.402 | Revisions Net=-3 | Growth EPS=-18.4% | Growth Revenue=-3.1%
EPS next Year (2027-12-31): EPS=2.42 | Chg7d=-0.354 | Chg30d=-0.353 | Revisions Net=-3 | Growth EPS=+7.9% | Growth Revenue=+1.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)